🇺🇸 FDA
Pipeline program

Mixed salts of a single-entity amphetamine

SLI381-316

Phase 3 small_molecule completed

Quick answer

Mixed salts of a single-entity amphetamine for Attention Deficit Disorder With Hyperactivity is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Attention Deficit Disorder With Hyperactivity
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials